Evidence map›Paper›PMID 37019471›Full record

ArticleJournal for immunotherapy of cancer2023

Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.

Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K Park, Audrey Jung, Jianming Lu, Sang-In Kim, Saul Priceman, Yuman Fong, Yanghee Woo

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05081492 phase1active not recruitingnot on this map

A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimeric Oncolytic Poxvirus Encoding Human Sodium Iodide Symporter (HNIS) in Patients With Metastatic Triple Negative Breast Cancer

TypeinterventionalSponsorCity of Hope Medical CenterRan2021 to 2027Enrolled9ConditionsAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8ArmsOncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
NCT05346484 phase1terminatednot on this map

A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).

TypeinterventionalSponsorImugene LimitedRan2022 to 2026Enrolled66ConditionsSolid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic CancerArmsCF33-hNIS, Pembrolizumab, Modified FOLFOX
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Oncolytic Virotherapy in Solid Tumors: A Current Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  11. Review
  12. Article
  13. Review
  14. Microbiota and gastric cancer: from molecular mechanisms to therapeutic strategies.Frontiers in cellular and infection microbiology · 2025
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Annie Yang *Department of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Zhifang Zhang *Department of Surgery, City of Hope National Medical Center, Duarte, California, USA yhwoo@coh.org zhzhang@coh.org.
Shyambabu ChaurasiyaDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Anthony K ParkCancer Immunotherapeutics Program, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0001-7692-8874
Audrey JungDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Jianming LuDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Sang-In KimDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Saul PricemanCancer Immunotherapeutics Program, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0002-8136-2112
Yuman FongDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Yanghee WooDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA yhwoo@coh.org zhzhang@coh.org.ORCID 0000-0002-6676-0593
City Of Hope National Medical Center · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Commercialization of the Shutter-Speed Model for Dynamic MRI in Cancer DiagnosisR44CA180425 · NCI · IMBIO, LLC · PI KEITH, LAUREN · 2013 to 2016
$1.8M
NCI NIH HHS P30 CA033572NCI NIH HHS R44 CA180425
6 · The paper itself

Abstract

backgroundGastric cancer (GC) that metastasizes to the peritoneum is fatal. CF33 and its genetically modified derivatives show cancer selectivity and oncolytic potency against various solid tumors. CF33-hNIS and CF33-hNIS-antiPDL1 have entered phase I trials for intratumoral and intravenous treatments of unresectable solid tumors (NCT05346484) and triple-negative breast cancer (NCT05081492). Here, we investigated the antitumor activity of CF33-oncolytic viruses (OVs) against GC and CF33-hNIS-antiPDL1 in the intraperitoneal (IP) treatment of GC peritoneal metastases (GCPM).

methodsWe infected six human GC cell lines AGS, MKN-45, MKN-74, KATO III, SNU-1, and SNU-16 with CF33, CF33-GFP, or CF33-hNIS-antiPDL1 at various multiplicities of infection (0.01, 0.1, 1.0, and 10.0), and performed viral proliferation and cytotoxicity assays. We used immunofluorescence imaging and flow cytometric analysis to verify virus-encoded gene expression. We evaluated the antitumor activity of CF33-hNIS-antiPDL1 following IP treatment (3×10

resultsCF33-OVs showed dose-dependent infection, replication, and killing of both diffuse and intestinal subtypes of human GC cell lines. Immunofluorescence imaging showed virus-encoded GFP, hNIS, and anti-PD-L1 antibody scFv expression in CF33-OV-infected GC cells. We confirmed GC cell surface PD-L1 blockade by virus-encoded anti-PD-L1 scFv using flow cytometry. In the xenograft model, CF33-hNIS-antiPDL1 (IP; 3×10

conclusionsOur results show that CF33-OVs can deliver functional proteins and demonstrate effective antitumor activity in GCPM models when delivered intraperitoneally. These preclinical results will inform the design of future peritoneal-directed therapy in GCPM patients.

Indexed as

Oncolytic VirotherapyOncolytic VirusesPeritoneal NeoplasmsStomach NeoplasmsAnimalsHumansMicePeritoneumimmunotherapyoncolytic virotherapyoncolytic viruses

Identifiers

PMID37019471
PMCPMC10083877
OpenAlexW4362607089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.